Occult Breast Carcinoma Presenting with Bilateral Axillary Disease: Clinicopathologic and Genomic Evidence for Independent Primaries OBC
Abstract
Background: Occult breast cancer (OBC) can present as axillary metastasis without an identifiable primary breast lesion. Bilateral axillary carcinomas pose a diagnostic challenge because mammary and nonmammary tumors may overlap morphologically and immunophenotypically.
Case Presentation: A 76-year-old woman presented with bilateral axillary masses, including a fungating ulcerated left axillary lesion. Mammography, ultrasonography, and breast MRI identified no primary breast lesion; PET/CT showed bilateral axillary disease without distant metastases. Initial core biopsies suggested invasive adenocarcinoma in both axillae with diffuse GATA3 expression supporting mammary differentiation. The right tumor showed HER2 IHC score 0 and Ki-67 of 30–40%. The left showed HER2 IHC score 1+ and Ki-67 of 6–10%. Both were ER 0% and PR 0%. Subsequent expert pathology review identified grade III invasive ductal carcinoma in the right lesion and keratinizing squamous cell carcinoma in the left lesion. Keratin-pearl formation and p63 positivity supported squamous differentiation in the left tumor. Targeted tumor sequencing identified PALB2 p.Y1108fs in both lesions, subsequently confirmed as germline by separate testing, along with otherwise nonoverlapping detected alterations: TP53, NF1, PTPRT, JAK1, and BCORL1 in the right tumor and a DDX41 splice-site variant in the left tumor.
Conclusion: This case highlights the diagnostic challenges of distinguishing mammary carcinoma from squamous cell carcinoma presenting as bilateral axillary masses. Integration of lesion location, morphology, immunophenotype, and molecular findings supported OBC on the right and squamous cell carcinoma on the left. These findings suggested potentially distinct origins of the two axillary masses, although definitive determination of the left tumor's origin remained limited by the available biopsy specimens.
References
Ofri A, Moore K. Occult breast cancer: where are we at? Breast. 2020;54:211-5. doi: 10.1016/j.breast.2020.10.012.
Miettinen M, McCue PA, Sarlomo-Rikala M, Rys J, Czapiewski P, Wazny K, et al. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol. 2014;38(1):13-22. doi: 10.1097/PAS.0b013e3182a0218f.
Rutland CD, Kingsley LG, Zdravkovic S, Vohra P, Chen YY, Krings G, et al. Immunohistochemical and molecular features distinguishing metaplastic breast carcinoma with squamous differentiation from cutaneous squamous cell carcinoma. Am J Surg Pathol. 2026;50(11):1372-87. doi: 10.1097/PAS.0000000000002601.
Miranda BH, Malahias M, El-Said TF, Fahmy FS. Axillary skin malignancy: a rare breast cancer presentation. Ann Plast Surg. 2014;72(5):513-4. doi: 10.1097/SAP.0b013e318268a915.
Youn HJ, Jung SH. Accessory breast carcinoma. Breast Care (Basel). 2009;4(2):104-6. doi: 10.1159/000210638.
de Bresser J, de Vos B, van der Ent F, Hulsewe K. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010;36(2):114-9. doi: 10.1016/j.ejso.2009.09.007.
Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, et al. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021;34(4):710-9. doi: 10.1038/s41379-020-00692-8.
Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127(1):103-13. doi: 10.1309/TDP92PQLDE2HLEET.
Rakha EA, Coimbra ND, Hodi Z, Juneinah E, Ellis IO, Lee AH. Immunoprofile of metaplastic carcinomas of the breast. Histopathology. 2017;70(6):975-85. doi: 10.1111/his.13159.
Bochtler T, Endris V, Leichsenring J, Reiling A, Neumann O, Volckmar AL, et al. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome. Int J Cancer. 2019;145(11):2963-73. doi: 10.1002/ijc.32316.
Chang JC, Alex D, Bott M, Tan KS, Seshan V, Golden A, et al. Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intrapulmonary metastases: comparison with standard histopathologic approach. Clin Cancer Res. 2019;25(23):7113-25. doi: 10.1158/1078-0432.CCR-19-1700.
Chang JC, Rekhtman N. Pathologic assessment and staging of multiple non-small cell lung carcinomas: a paradigm shift with the emerging role of molecular methods. Mod Pathol. 2024;37(5):100453. doi: 10.1016/j.modpat.2024.100453.
Authors
Copyright (c) 2026 Jin Zheng, Xu Wang, Gary Becker, M Rashid Chaudhry, Richard Wu, Andrea Richardson, Jen Chin Wang

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.